WHAT YOU NEED TO KNOW CAPA: The USPTO must prioritize patent quality and restore the IPR system to its proper focus. UPDATE – As part of its ongoing campaign to safeguard the U.S. patent system and stop Big Pharma from gaming the system, CAPA filed comments this week with the United States Patent and Trademark Office (USPTO).  The […]

Continue Reading

WHAT YOU NEED TO KNOW BREAKING NEWS: CAPA releases guidance for next Administration and Congress encouraging Washington to address Big Pharma’s abuses of the patent system that keeps drug prices high for patients and the entire U.S. healthcare system.  Continued exploitations of the U.S. patent process results in deadweight losses that get saddled on the backs […]

Continue Reading

WHAT YOU NEED TO KNOW A must-read report was recently released – The 2020 Access and Savings Report by the Association for Accessible Medicines (AAM) – a member of CAPA – that highlights the critical benefits of increasing access to alternative prescription drugs which can drive affordability for not only American patients, but the healthcare system as […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, the Coalition Against Patent Abuse applauded a recent decision by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing practices by the big drug companies.   “CAPA applauds today’s announcement by the […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a national survey by the Campaign for […]

Continue Reading

WHAT YOU NEED TO KNOW This week, Axios reported that Humira, a medicine that is prescribed to millions of people around the world, “continues to generate more U.S. revenue than any other drug, due to AbbVie extending U.S. patents and consequently retaining higher U.S. prices.”   WHAT YOU NEED TO KNOW: While Humira is notably one of the […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy.  The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the field, […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, I-MAK released a new report that outlines how AbbVie abuses the U.S. patent system to stave off competition for their critical cancer drug, Imbruvica.  This analysis was also covered by STAT News which showed AbbVie could have its patents on Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse (CAPA) along with Niskanen Center, Engine, R Street Institute and other public and private interest groups signed on to a letter sent to the House and Senate Judiciary Committees encouraging them to exercise their oversight authority to investigate procedural changes recently made by the Patent […]

Continue Reading

WHAT YOU NEED TO KNOW Last week, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy. The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the […]

Continue Reading